Holen Sie sich die Stockscreener-App
3.50
12.90%
0.40
Schlusskurs vom Vortag:
$3.10
Offen:
$3.24
24-Stunden-Volumen:
115.21K
Relative Volume:
1.85
Marktkapitalisierung:
$10.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.89M
KGV:
-0.6215
EPS:
-5.6317
Netto-Cashflow:
$-10.96M
1W Leistung:
-13.15%
1M Leistung:
-27.39%
6M Leistung:
-52.51%
1J Leistung:
-73.86%
1-Tages-Spanne:
$3.15
$3.60
1-Wochen-Bereich:
$3.02
$4.24
52-Wochen-Spanne:
$3.02
$14.64
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Firmenname
Cadrenal Therapeutics Inc
Sektor
Branche
Telefon
904-300-0701
Adresse
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
3.50 | 10.77M | 0 | -11.89M | -10.96M | -5.6317 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-18 | Eingeleitet | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Aktie (CVKD) Neueste Nachrichten
Cadrenal CEO Pham sells $13,110 in company stock By Investing.com - Investing.com India
Cadrenal CEO Pham sells $13,110 in company stock - Investing.com
Cadrenal (CVKD) CEO Pham sells 4,126 shares, retains large stake via trust - Stock Titan
Cadrenal Therapeutics (CVKD) Pursues FDA Designation for Pediatric Treatment - GuruFocus
Cadrenal plans rare pediatric disease designation for tecarfarin - Investing.com
Cadrenal Pursues Rare Pediatric Designation for Tecarfarin - TipRanks
Cadrenal Therapeutics To Submit FDA Rare Pediatric Disease Designation Request For Tecarfarin In Kawasaki Disease - TradingView
Pediatric voucher play: Cadrenal (NASDAQ: CVKD) eyes tecarfarin RPDD - Stock Titan
Cadrenal targets FDA rare pediatric status for tecarfarin in Kawasaki disease - Stock Titan
Cadrenal Therapeutics Inc (CVKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cadrenal Therapeutics Inc (CVKD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cadrenal Therapeutics Inc (CVKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cadrenal Therapeutics Inc (CVKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cadrenal Therapeutics Inc (CVKD) Institutional Confidence - TradingKey
Cadrenal Therapeutics Inc (CVKD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cadrenal Therapeutics Inc (CVKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cadrenal Therapeutics Inc (CVKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cadrenal Therapeutics Inc (CVKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cadrenal Therapeutics chairman, CEO Pham sells $70,351 in shares - Investing.com UK
Cadrenal Therapeutics chairman, CEO Pham sells $70,351 in shares By Investing.com - Investing.com Canada
Cadrenal (CVKD) CEO sells shares under Rule 10b5-1 trading plan - Stock Titan
CVKD (NASDAQ: CVKD) Form 144 lists Quang X. Pham sales of common stock - Stock Titan
Cadrenal Therapeutics Advances Multi-Indication Strategy For CAD-1005 And Launches Phase 2a Acute Kidney Injury Clinical Plan - marketscreener.com
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 - The Manila Times
New trial targets kidney injury after heart surgery in $1B market - Stock Titan
Cadrenal Therapeutics (CVKD) Slips 8% Amid Selling Pressure, Testing Key Support LevelsPut Call Ratio - newsline.com
CVKD Q1 2026 Earnings: Narrower-Than-Expected Loss Provides Temporary ReliefNet Income Trends - newsline.com
CVKD Q1 2026 Earnings: EPS beats estimates despite pre-revenue stageGuidance vs Actual - newsline.com
Cadrenal Therapeutics CEO Pham sells $93,293 in common stock By Investing.com - Investing.com South Africa
Cadrenal Therapeutics CEO Pham sells $93,293 in common stock - Investing.com
Cadrenal (NASDAQ: CVKD) CEO sells 22,385 shares but keeps large stake - Stock Titan
CVKD Q1 2026 Earnings: Narrower-Than-Expected Loss as Company Advances Rare Disease PipelineEPS Growth Report - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
Cadrenal Therapeutics CEO Quang Pham sells $36,209 in stock By Investing.com - Investing.com Australia
Cadrenal Therapeutics CEO Quang Pham sells $36,209 in stock - Investing.com
Cadrenal Therapeutics (CVKD) CEO sells 8,285 shares in planned trades - Stock Titan
Cadrenal Therapeutics Announces CFO Transition and Interim Appointment - The Globe and Mail
According to the latest filing with the U.S. Securities and Exchange Commission (SEC), Cadrenal Therapeutics, Inc. has officially appointed Quang X. Pham as the company's interim Chief Financial Officer and interim Chief Accounting Officer. - Bitget
Cadrenal Therapeutics Says Matthew Szot Steps Down As CFOSEC Filing - TradingView
Cadrenal (NASDAQ: CVKD) CFO exits as CEO takes interim finance role - Stock Titan
Cadrenal Therapeutics, Inc. Announces CFO Changes, Effective May 28, 2026 - marketscreener.com
Cadrenal’s CAD-1005, a HIT clot drug, targets $2B market as Phase 3 looms - Stock Titan
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event - marketscreener.com
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 - GlobeNewswire
Cadrenal Therapeutics CEO Pham sells $3,074 in common stock - Investing.com UK
Cadrenal Therapeutics CEO Pham sells $3,074 in common stock By Investing.com - Investing.com South Africa
Cadrenal Therapeutics (CVKD) CEO logs 652-share Rule 10b5-1 stock sale - Stock Titan
CVKD Q1 2026 Earnings: EPS Beat with 37% Surprise; Stock Declines SlightlyReturn On Capital - newsline.com
CVKD Q1 2026 Earnings: Narrower EPS Loss Surprises as Development Pipeline AdvancesEstimate Uncertainty - The Legal Advocate
Cadrenal (CVKD) CEO sells 12,763 shares, retains direct and trust holdings - Stock Titan
Cadrenal Therapeutics Q1 2026 Earnings: Narrowed Loss Surpasses Estimates, Stock Edges HigherEPS Growth Rate - The Legal Advocate
Finanzdaten der Cadrenal Therapeutics Inc-Aktie (CVKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):